```json
{
"content": [
{
"type": "paragraph",
"content": "North America dominates the mRNA Vaccines & Therapeutics market growth with a 42% share, underpinned by the FDA’s adaptive regulatory pathway, biotech mega-clusters along Boston–San Diego axis, and >US$5 bn post-COVID federal booster contracts that de-risk scale-up; reimbursement codes already reimburse personalized cancer mRNA shots, accelerating regional forecast momentum."
},
{
"type": "paragraph",
"content": "Europe (28%) leverages EMA’s PRIME scheme, EU4Health’s €9 bn manufacturing fund, and ageing 65+ cohort to anchor procurement; CEPI’s Oslo-based network guarantees equitable access, while Germany’s BioNTech success cements an innovation flywheel."
},
{
"paragraph",
"content": "Asia Pacific is the fastest-growing region (18% share, 24% CAGR) as Japan’s PMDA fast-tracks mRNA oncology, China’s “Made 2025” offers 30% CapEx subsidies, and India’s Serum-CSIR alliance ramps low-cost lipid supply chains; expanding middle class and proactive genomic surveillance are propelling regional forecast upside."
},
{
"type": "paragraph",
"content": "Latin America (8%) sees Brazil’s Fiocruz tech-transfer deals, PAHO revolving fund pooled procurement, and dengue mRNA trials that secure WHO PQ listing; digital immunization registries mitigate cold-chain gaps, driving mRNA Vaccines & Therapeutics market growth."
},
{
"type": "paragraph",
"content": "Middle East & Africa (4%) is catalysed by UAE’s 4th-dose mandates, Saudi genomics biobank (500k genomes), and Afreximbank’s US$2 bn pandemic facility; however, talent outflow and GMP plant shortages temper near-term regional forecast peaks."
}
],
"worldMapData": {
"regions": [
{ "name": "North America", "value": 42 },
{ "name": "Europe", "value": 28 },
{ "name": "Asia Pacific", "value": 18 },
{ "name": "Latin America", "value": 8 },
{ "name": "Middle East & Africa", "value": 4 }
]
}
}
```
